Following adults with obesity who have an endoscopic stomach-reducing procedure in France
Follows adults with obesity who undergo endoscopic sleeve gastroplasty, checking safety and results.
Plain-language title generated from the registry record
Registry title: Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Key facts
- Where
- Baie-Mahault, GuadeloupeSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07449520, who can take part
Where in Guadeloupe
- Clinique les Eaux ClairesBaie-Mahault, GuadeloupeNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- IHU Strasbourg
- Trial code
- NCT07449520
- Record updated
- 6 November 2026
- Original description
EGO-Trial is the first multicenter study in France which aims to evaluate the efficacy of Endoscopic Sleeve Gastroplasty (ESG) in patients with obesity. This project fills a critical national gap by providing real-world, multicentric data from diverse French healthcare settings, offering insight into the safety, efficacy, and variability of ESG practices across institutionsRead full original descriptionShow less
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity
EGO-Trial is the first multicenter study in France which aims to evaluate the efficacy of Endoscopic Sleeve Gastroplasty (ESG) in patients with obesity. This project fills a critical national gap by providing real-world, multicentric data from diverse French healthcare settings, offering insight into the safety, efficacy, and variability of ESG practices across institutions
The project is expected to generate robust, multicentric clinical evidence on the safety and efficacy of ESG in patients with obesity within the French healthcare context.
Inclusion: Patients aged 18 to 75 years; Patients with a Body Mass Index (BMI) ≥ 30 kg/m²; Patients who have failed non-surgical weight loss interventions (diet, exercise, pharmacological therapy); Patients not eligible for bariatric surgery or does not wish to undergo it; Patients who can undergo general anesthesia; Patients who are able to participate in all aspects of the study and agree to comply with all study requirements for the entire duration of the study; Patients who are able to fully understand the study and are willing to give their consent to participate in the study; Patients affiliated with the French social security system.
Exclusion: Patients who have started medication in the last 3 months that is known to cause weight gain; Patients who are currently excluded (as determined by a previous or ongoing study); Patients with active peptic ulcer disease or significant gastroparesis; Patients with a history of bariatric, gastric, or esophageal surgery; Patients with a history of uncontrolled, poorly controlled, or suspected eating disorders or psychiatric illness; Patients who are pregnant, breastfeeding, or of childbearing age and not using effective contraception; Patients with contraindications to endoscopic gastroplasty; Patients with unstable and precarious health, as determined and assessed by the investigator; Patients under judicial protection; Patients under guardianship, conservatorship or subject to any form of protective supervision.